NCT03207555View on ClinicalTrials.gov

Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

May 23, 2018

Primary Completion Date

August 2, 2024

Study Completion Date

August 2, 2024

Conditions
Malignant Neoplasms Stated as Primary Lymphoid HaematopoieticChronic Lymphocytic LeukemiaSmall Lymphocytic Leukemia
Interventions
DRUG

Ibrutinib

420 mg by mouth once daily.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Pharmacyclics LLC.
All Listed Sponsors
collaborator

Pharmacyclics LLC.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT03207555 - Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL) | Biotech Hunter | Biotech Hunter